Collaborative Atorvastatin Diabetes Study (CARDS)
Jump to navigation
Jump to search
Introduction
Study in UK & Ireland
Study characteristics:
- 2838 type 2 diabetic patients
- age 40-75 years
- no history of cardiovascular disease
- LDL-cholesterol < 160 mg/dL
- fasting serum triglycerides < 616 mg/dL
- all patients had retinopathy, albuminuria, hypertension or were current smokers
atorvastatin 10 mg QD vs placebo
Primary endpoints:
Results:
- trial stopped after 4 years because fewer patients in the atorvastatin group reached primary endpoint
- atorvastatin was not associated with excess toxicity, even when LDL-cholesterol was lowered to < 40 mg/dL
More general terms
Additional terms
References
- ↑ Journal Watch 24(19):149, 2004 Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21;364(9435):685-96. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15325833
Garg A. Statins for all patients with type 2 diabetes: not so soon. Lancet. 2004 Aug 21;364(9435):641-2. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15325810 - ↑ Thomason MJ, Colhoun HM, Livingstone SJ, Mackness MI, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Fuller JH; CARDS Investigators. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabet Med. 2004 Aug;21(8):901-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15270795